Display options
Cite
Moraes L, Zanchin NIT, Cerutti JM. ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway. Oncotarget. 2017;8(40):67769-67781doi: 10.18632/oncotarget.18840.
Moraes, L., Zanchin, N. I. T., & Cerutti, J. M. (2017). ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway. Oncotarget, 8(40), 67769-67781. https://doi.org/10.18632/oncotarget.18840
Moraes, Lais, et al. "ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway." Oncotarget vol. 8,40 (2017): 67769-67781. doi: https://doi.org/10.18632/oncotarget.18840
Moraes L, Zanchin NIT, Cerutti JM. ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway. Oncotarget. 2017 Jun 29;8(40):67769-67781. doi: 10.18632/oncotarget.18840. eCollection 2017 Sep 15. PMID: 28978070; PMCID: PMC5620210.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 29;8(40):67769-67781. doi: 10.18632/oncotarget.18840. eCollection 2017 Sep 15.

ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway.

Oncotarget

Lais Moraes, Nilson I T Zanchin, Janete M Cerutti

Affiliations

  1. Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
  2. Instituto Carlos Chagas, Fundação Oswaldo Cruz/FIOCRUZ, Curitiba, Paraná, Brazil.

PMID: 28978070 PMCID: PMC5620210 DOI: 10.18632/oncotarget.18840

Abstract

We previously reported that

Keywords: ABI3; CYFIP1; PI3K/AKT; WAVE2; follicular thyroid carcinoma

Conflict of interest statement

CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.

References

  1. Cell. 2014 Oct 23;159(3):676-90 - PubMed
  2. Anticancer Res. 2014 May;34(5):2185-94 - PubMed
  3. Am J Pathol. 2001 Mar;158(3):987-96 - PubMed
  4. Dev Cell. 2014 Sep 8;30(5):569-84 - PubMed
  5. Electrophoresis. 2010 Mar;31(6):1080-9 - PubMed
  6. Cancer Res. 2002 Apr 15;62(8):2215-9 - PubMed
  7. Genes Dev. 1995 Nov 1;9(21):2569-82 - PubMed
  8. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4379-83 - PubMed
  9. Biosci Rep. 2014 Apr 1;34(2): - PubMed
  10. Mol Cell Proteomics. 2011 Mar;10(3):M110.000927 - PubMed
  11. Cell. 2014 Jan 16;156(1-2):195-207 - PubMed
  12. BMC Cancer. 2011 Jan 11;11:11 - PubMed
  13. Nat Rev Mol Cell Biol. 2007 Jan;8(1):37-48 - PubMed
  14. Nature. 2002 Aug 15;418(6899):790-3 - PubMed
  15. Thyroid. 2010 Jul;20(7):697-706 - PubMed
  16. Blood. 2010 Jan 14;115(2):296-305 - PubMed
  17. FEBS Lett. 2012 Aug 14;586(17):2790-4 - PubMed
  18. Cell. 2010 Dec 23;143(7):1174-89 - PubMed
  19. Cell Commun Signal. 2015 Oct 01;13:41 - PubMed
  20. Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1098-103 - PubMed
  21. Clin Cancer Res. 2006 Apr 15;12(8):2449-54 - PubMed
  22. Endocr Relat Cancer. 2008 Sep;15(3):787-99 - PubMed
  23. BMC Bioinformatics. 2013 Apr 15;14:128 - PubMed
  24. Biochim Biophys Acta. 2007 May;1773(5):642-52 - PubMed
  25. J Biol Chem. 2006 Oct 20;281(42):31290-7 - PubMed
  26. Oncotarget. 2016 May 3;7(18):25960-70 - PubMed
  27. Cell. 2000 Oct 13;103(2):239-52 - PubMed
  28. Oncogene. 2005 Feb 17;24(8):1309-19 - PubMed
  29. PLoS One. 2012;7(4):e34514 - PubMed
  30. Mol Cell Biol. 2002 Nov;22(22):7731-43 - PubMed
  31. FEBS Lett. 2006 Nov 27;580(27):6464-70 - PubMed
  32. Cell. 2009 Jun 12;137(6):1047-61 - PubMed
  33. Cancer Res. 2010 Nov 15;70(22):9349-59 - PubMed
  34. Anal Chem. 2010 Feb 1;82(3):824-32 - PubMed
  35. J Cell Biol. 2007 Feb 26;176(5):667-80 - PubMed
  36. Thyroid. 2005 Jun;15(6):551-61 - PubMed
  37. PLoS One. 2012;7(4):e34677 - PubMed
  38. Nature. 2010 Nov 25;468(7323):533-8 - PubMed

Publication Types